AbbVie Inc. (ABBV) Net Income CAGR:-13.26%(TTM)
The net income cagr for AbbVie Inc. (ABBV) is -13.26% over the latest trailing 12-month period. Net income CAGR uses precomputed financial statement history.
The net income cagr for AbbVie Inc. (ABBV) stock is -13.26% over the past 12 months. The 3 year average growth rate is -21.71% and the 5 year cagr is -6.74%. Net income CAGR shows how AbbVie Inc.'s bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
ABBV Net Income CAGR Chart
AbbVie Inc. (ABBV)
ABBV Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $4.28B | $4.23B | $-52.00M | -1.22% | -1.22% |
| 2024 | $4.86B | $4.28B | $-585.00M | -12.03% | -12.03% |
| 2023 | $11.84B | $4.86B | $-6.97B | -58.91% | -58.91% |
| 2022 | $11.54B | $11.84B | +$294.00M | +2.55% | +2.55% |
| 2021 | $4.62B | $11.54B | +$6.93B | +150.04% | +150.04% |
| 2020 | $7.88B | $4.62B | $-3.27B | -41.44% | -41.44% |
| 2019 | $5.69B | $7.88B | +$2.19B | +38.60% | +38.60% |
| 2018 | $5.31B | $5.69B | +$378.00M | +7.12% | +7.12% |
| 2017 | $5.95B | $5.31B | $-644.00M | -10.82% | -10.82% |
| 2016 | $5.14B | $5.95B | +$809.00M | +15.73% | +15.73% |
| 2015 | $1.77B | $5.14B | +$3.37B | +189.97% | +189.97% |
| 2014 | $4.13B | $1.77B | $-2.35B | -57.03% | -57.03% |
| 2013 | $5.28B | $4.13B | $-1.15B | -21.74% | -21.74% |
| 2012 | $3.43B | $5.28B | +$1.84B | +53.66% | +53.66% |
| 2011 | $4.18B | $3.43B | $-745.00M | -17.83% | -17.83% |
| 2010 | $4.64B | $4.18B | $-458.51M | -9.89% | -9.89% |
Quarterly Net Income — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $699.00M | -61.5% | -45.6% |
| Q4 2025 | $1.82B | +876.3% | +8354.5% |
| Q3 2025 | $186.00M | -80.2% | -88.1% |
| Q2 2025 | $938.00M | -27.1% | -31.5% |
| Q1 2025 | $1.29B | +5945.5% | -6.1% |
| Q4 2024 | -$22.00M | -101.4% | -102.7% |
| Q3 2024 | $1.56B | +13.9% | -12.2% |
| Q2 2024 | $1.37B | +0.1% | -32.3% |
| Q1 2024 | $1.37B | +66.5% | +472.8% |
| Q4 2023 | $822.00M | -53.8% | -66.8% |
| Q3 2023 | $1.78B | -12.2% | -55.0% |
| Q2 2023 | $2.02B | +746.9% | +119.0% |
| Q1 2023 | $239.00M | -90.3% | -94.7% |
| Q4 2022 | $2.47B | -37.4% | -38.8% |
| Q3 2022 | $3.95B | +327.4% | +24.2% |
| Q2 2022 | $924.00M | -79.4% | +20.6% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael